In fact, in the avoren [Avastin (Genentech, San Francisco, CA, U.S.A.)for Renal Cell Cancer] trial, the combination was less well tolerated than was interferon alone, whereas vegfr-tkis are generally better tolerated than interferon is. This evidence concerns the gene KDR and renal cell adenocarcinoma.